Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients

European Journal of Gynaecological Oncology

Volumn 26, Issue 1, 2005, Pages 43-46

  Opala, T ^a   Rzymski, P ^a,b   Wilczak, M ^a   Wozniak J ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Hospital   (Poland)

Author keywords

Cancer; Ovarian; Receptor 1; Receptor 2; TNF ; Tumour marker

Indexed keywords

CA 125 ANTIGEN; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREOPERATIVE EVALUATION; PROTEIN DETERMINATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 14644399179     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chen G., Goeddel D.V.: "TNF-R1 signaling: a beautiful pathway". Science, 2002, 296, 1634.
2. Medvedev A., Espevik T., Ranges T. et al.: "Distinct roles of two tumor necrosis factor (TNF) receptors in modultaing TNF and lymphotoxin α effects". J. Biol. Chem., 1996, 271, 9778.
3. Kost E.R., Herzog T.J., Adler L.M. et al.: "The role of tumor necrosis factor receptors in tumor necrosis factor-α-mediated cytolysis of ovarian cancer cell lines". Am. J. Obstet. Gynecol., 1996, 174, 145.
4. Bigda J., Beletsky I., Brakebush C. et al.: "Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity". J. Exp. Med., 1994, 180, 445.
5. Tartaglia A.T., Pennica D., Goedddel D.V.: "Ligand passing: the 75kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor". J. Biol. Chem., 1993, 268, 18542.
6. Olsson I., Gatanga T., Bullberg U. et al.: "Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy". Eur. Cytokine Netw., 1993, 4, 169.
7. Bazzoni F., Beutler B., Flier J. et al.: "The tumor necrosis factor ligand and receptor families". N. Engl. J. Med., 1996, 334, 1717.
8. Brockhaus M., Schoenfeld H.J., Schlager E.J. et al.: "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies". Proc. Natl. Acad. Sci., 1990, 87, 3127.
9. Sancho-Tello M., Marcinkiewicz J.L., Justice W.M. et al.: "Reduction of tumor necrosis factor-α bioactivity by a human ovarian epithelial cancer cell line in vitro". Am. J. Obstet. Gynecol., 1995, 173, 1470.
10. Myamon E., Ghezzi F., Edwin S.S. et al.: "The tumor necrosis factor α and its soluble receptor profile in term and preterm partuition". Am. J. Obstet. Gynecol., 1999, 181, 1142.
11. Gadducci A., Ferdeghini M., Castellani C. et al.: "Serum levels of Tumor Necrosis Factor (TNF), soluble receptors for TNF (55- and 75-kDA sTNFr) and soluble CD14 (sCD14) in epithelial ovarian cancer". Gynecol. Oncol., 1995, 58, 184.
12. Naylor M.S., Stamp G.W.H., Foulkes W.D. et al.: "Tumor necrosis factor and its receptors in human ovarian cancer - potential role in disease progression". J. Clin. Invest., 1993, 91, 2194.
13. Onsrud M., Shabana A., Austgulen R. et al.: "Comparison between soluble Tumor Necrosis Factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer". Gynecol. Oncol., 1995, 57, 183.
14. Ferrazzi E., Zanetta G., Dordoni D. et al.: "Transvaginal ultrasonographic characterisation of ovarian masses: comparison of five scoring system in a multicenter study". Ultrasound Obstet. Gynecol., 1997, 10, 192.
15. Metz C.E., Herman B.A., Roe C.A.: "Statistical comparison of two ROC curve estimates obtained from partially-paired datasets". Med. Decis. Making, 1998, 18, 110.
16. Topalak O., Saygili U., Soyturk M. et al.: "Serum, pleural effusion and ascites CA125 levels in ovarian cancer and nonovarian benign and malignant disease: a comparative study". Gynecol. Oncol., 2002, 85, 108.
17. Aslam N., Tailor A., Lawton F. et al.: "Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer". B.J.O.G., 2000, 107, 1347.
18. Menon U., Talaat A., Rosenthal A.N. et al.: "Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening". B.J.O.G., 2002, 107, 165.
19. Sjövall K., Nilsson B., Einhorn N.: "The significance of serum CA125 elevation in malignant and nonmalignant disease". Gynecol. Oncol., 2002, 85, 175.
20. Berek J.S., Bast R.C.: "Ovarian cancer screening". Cancer, 1995, 76, 2092.
21. Markowska J., Wilkoszarska J.: "The value of CA 125 levels in serum, peritoneal fluid and tumor in women with ovarian cancer". Gin. Pol., 1996, 67, 352.
22. Viac J., Vincent C., Palacio S. et al.: "Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels". Eur. J. Cancer, 1996, 32, 447.